Lead

Polycystic ovary syndrome (PCOS), a condition affecting one in eight women, has been renamed polyendocrine metabolic ovarian syndrome (PMOS) after more than a decade of global collaboration. The name change, published in The Lancet and announced at the European Congress of Endocrinology in Prague, reflects a growing recognition that the previous term was misleading and contributed to delayed diagnosis and inadequate care.

The renaming initiative was led by Professor Helena Teede, director of the Monash Centre for Health Research and Implementation in Melbourne. The new name aims to better describe the condition's complex nature, which affects not only the reproductive system but also metabolism and the risk of diabetes and cardiovascular disease.

Coverage Comparison

Both ABC Australia and The Guardian — World covered the renaming, though their emphases differed. ABC Australia's reports were predominantly informative, focusing on the announcement itself and the underlying research, while The Guardian — World approached the story from a more personal angle, featuring patient narratives about struggles to receive a diagnosis and adequate care. The Guardian also noted that the new name will be fully implemented in the next update to international guidelines for managing the condition, scheduled for 2028.

The scientific basis for the change was reinforced by a separate study of 1,235 Finnish women, published in JAMA Internal Medicine, which found that women with PCOS do not have a higher rate of abnormal ovarian cysts than women without the condition. The Finnish researchers, led by Professor Terhi Piltonen of the University of Oulu, said their findings supported the push to change the name, as the concern about pathological cysts was unfounded.

Key Claims

  • PCOS renamed PMOS: The condition formerly known as polycystic ovary syndrome is now called polyendocrine metabolic ovarian syndrome, as reported by both sources and published in The Lancet.
  • Study on cysts: A study of 1,235 Finnish women found no increased rate of abnormal ovarian cysts in women with PCOS, according to a report by ABC Australia.
  • Complex nature: The new name emphasizes the condition's impact on metabolism, diabetes and cardiovascular risk, as reported by ABC Australia and The Guardian.
  • Global consultation: The change follows 14 years of collaboration involving international societies and patient groups across six continents, as detailed by ABC Australia.
  • No cure: PCOS has no cure, but symptoms can be managed with medical consultation, as reported by ABC Australia.
  • Symptoms: Women with PCOS may experience irregular or absent periods, or long and heavy ones, according to ABC Australia.
  • Prevalence: PCOS affects about one in eight women, according to ABC Australia.
  • Implementation: The new name will be incorporated into international guidelines in the 2028 update, as reported by The Guardian.

Perspectives

Professor Helena Teede (endocrinologist and director, Monash Centre for Health Research and Implementation) argued that the condition's previous name was "very inaccurate," reducing a complex, lifelong disorder to a misunderstanding about cysts and focusing disproportionate attention on the ovaries. She said the change "validates what a lot of women know and experience."

Patients and advocates expressed relief and hope. Maddy Mavrikis, who was diagnosed at 15, said she never had cysts on her ovaries and never understood why the condition was called "polycystic ovaries." She welcomed the change as a step toward better care and understanding. The Guardian reported that patients and professionals supported the name change.

Researcher (Finnish study lead) Terhi Piltonen highlighted that the condition is lifelong, affecting several organs and having "vast endocrinological, metabolic and psychological health outcomes," adding that the study's findings underline the inaccuracy of the term.